EyePoint Inc EYPT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
-
These beaten-down stocks could bounce back in January, if history is any guide
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
-
Investigation Alert: EyePoint, Inc. (EYPT) Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
-
EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Trading Information
- Previous Close Price
- $3.14
- Day Range
- $2.95–3.15
- 52-Week Range
- $2.93–19.11
- Bid/Ask
- $3.00 / $3.19
- Shares Outstanding
- 86.21M
- Market Cap
- $257.77M
- Volume/Avg
- 3M / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 89.67
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 214
- Website
- https://www.eyepoint.bio
Valuation
|
Metric
|
EYPT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.57 |
Price/Sales | 89.67 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
EYPT
|
|---|---|
Quick Ratio | 4.30 |
Current Ratio | 4.50 |
Interest Coverage | — |
Quick Ratio
EYPT
Profitability
|
Metric
|
EYPT
|
|---|---|
Return on Assets (Normalized) | −97.27% |
Return on Equity (Normalized) | −121.31% |
Return on Invested Capital (Normalized) | −114.55% |
Return on Assets
EYPT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|pj&c?km | LOCK|g<k<S | $127B | |||
| Moderna Inc
MRNA
| LOCK|P@P#Ldx | LOCK|?^ | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$^#g#$ | LOCK|Y<%T | $81B | |||
| argenx SE ADR
ARGX
| LOCK|slf?Nb> | LOCK|GJ# | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%<<q&! | LOCK|^!Y | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?RbDgwJ | LOCK|Zzx^ | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&z&#z<t | LOCK|NSd> | $27B | |||
| Incyte Corp
INCY
| LOCK|dmQ>m? | LOCK|?j# | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|s?mKZt | LOCK|cT | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|qNWx%%b | LOCK|G% | $14B |
United States